Recombinant Activated Factor VII in Obstetric Hemorrhage: Experiences from the Australian and New Zealand Haemostasis Registry
Louise E Phillips, Claire McLintock, Wendy Pollock, Stephen Gatt, Philip Popham, Gary Jankelowitz, Robert Ogle, Peter A Cameron
ANESTHESIA AND ANALGESIA | LIPPINCOTT WILLIAMS & WILKINS | Published : 2009
OBJECTIVE: Through the Australian and New Zealand Haemostasis Registry, we report on the Australian and New Zealand experience with recombinant activated factor VII (rFVIIa) in obstetric patients. METHODS: The role of rFVIIa for off-label indications, including trauma, cardiac surgery, and severe postpartum hemorrhage, remains controversial. The Haemostasis Registry established by Monash University in Melbourne, Australia monitors off-label use of rFVIIa across Australia and New Zealand. The purpose of this study was to summarize Registry data for all obstetric hemorrhage patients treated with rFVIIa at participating hospitals between January 2002 and July 2008. The primary outcome measures ..View full abstract
The Australian and New Zealand Haemostasis Registry is financially supported through an educational grant from Novo Nordisk Pharmaceuticals Pty. Ltd.